Encompass Health Co. (NYSE:EHC) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP lessened its position in shares of Encompass Health Co. (NYSE:EHC - Free Report) by 72.0% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,140 shares of the company's stock after selling 41,537 shares during the period. Bridgewater Associates LP's holdings in Encompass Health were worth $1,560,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in EHC. UMB Bank n.a. lifted its stake in shares of Encompass Health by 387.7% in the 3rd quarter. UMB Bank n.a. now owns 317 shares of the company's stock valued at $31,000 after purchasing an additional 252 shares in the last quarter. V Square Quantitative Management LLC lifted its position in Encompass Health by 53.0% during the third quarter. V Square Quantitative Management LLC now owns 404 shares of the company's stock valued at $39,000 after buying an additional 140 shares in the last quarter. Avior Wealth Management LLC purchased a new stake in Encompass Health during the third quarter worth approximately $40,000. Oakworth Capital Inc. acquired a new stake in shares of Encompass Health in the second quarter worth $40,000. Finally, Benjamin F. Edwards & Company Inc. raised its stake in shares of Encompass Health by 58.9% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 534 shares of the company's stock valued at $46,000 after acquiring an additional 198 shares during the period. 97.25% of the stock is currently owned by institutional investors and hedge funds.

Encompass Health Stock Down 0.5 %

Shares of EHC stock traded down $0.54 during mid-day trading on Monday, reaching $102.40. 521,080 shares of the company were exchanged, compared to its average volume of 639,801. The company has a market capitalization of $10.32 billion, a P/E ratio of 24.71, a P/E/G ratio of 1.36 and a beta of 0.88. The business's 50 day simple moving average is $98.16 and its 200 day simple moving average is $91.45. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.04 and a current ratio of 1.04. Encompass Health Co. has a fifty-two week low of $64.15 and a fifty-two week high of $104.55.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Monday, October 28th. The company reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.94 by $0.09. The business had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.33 billion. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. The company's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.86 EPS. Research analysts predict that Encompass Health Co. will post 4.29 earnings per share for the current year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be issued a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.66%. Encompass Health's dividend payout ratio (DPR) is 16.43%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on EHC shares. UBS Group upped their price target on shares of Encompass Health from $100.00 to $110.00 and gave the stock a "buy" rating in a research report on Wednesday, September 25th. Truist Financial reiterated a "buy" rating and issued a $116.00 target price (up previously from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. KeyCorp boosted their price target on Encompass Health from $115.00 to $117.00 and gave the stock an "overweight" rating in a research report on Tuesday, October 29th. Barclays increased their price objective on shares of Encompass Health from $109.00 to $116.00 and gave the company an "overweight" rating in a research report on Tuesday, October 29th. Finally, Royal Bank of Canada boosted their target price on shares of Encompass Health from $105.00 to $110.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 30th. Nine equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Encompass Health currently has an average rating of "Buy" and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.